Bi­par­ti­san House bill seeks to boost pe­di­atric drug de­vel­op­ment via new FDA penal­ties for non­com­pli­ance

A bi­par­ti­san duo of law­mak­ers is seek­ing to boost pe­di­atric drug de­vel­op­ment with new leg­is­la­tion that would pri­or­i­tize adding pe­di­atric pa­tients to tri­als for new …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER